ARS Pharmaceuticals, Inc. (SPRY) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
11682 EL CAMINO REAL, SUITE 300 SAN DIEGO, CA 92130 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 314,022 | 228,360 | 274,381 | 254,045 | |||
| Cash and cash equivalent | 50,817 | 70,971 | 210,518 | 254,045 | |||
| Short-term investments | 263,205 | 157,389 | 63,863 | ||||
| Receivables | 8,831 | 178 | 16 | ||||
| Inventory, net of allowances, customer advances and progress billings | 5,212 | ||||||
| Inventory | 5,212 | ||||||
| Prepaid expense | 1,261 | 904 | 1,539 | ||||
| Other undisclosed current assets | 4,969 | 2,284 | 1,764 | 7,447 | |||
| Total current assets: | 334,295 | 231,726 | 277,700 | 261,492 | |||
| Noncurrent Assets | |||||||
| Inventory, Noncurrent | 5,307 | ||||||
| Operating lease, right-of-use asset | 37 | 250 | 445 | 4,733 | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 1,029 | 574 | 329 | 2,212 | |||
| Long-term investments and receivables | 64,780 | ||||||
| Long-term investments | 64,780 | ||||||
| Intangible asset, including goodwill, after accumulated amortization | 7,371 | ||||||
| Intangible asset, excluding goodwill, after accumulated amortization | 7,371 | ||||||
| Prepaid expense | 2,940 | ||||||
| Restricted cash and investments | 250 | ||||||
| Other undisclosed noncurrent assets | 3,114 | 638 | 21 | ||||
| Total noncurrent assets: | 16,858 | 1,462 | 3,735 | 71,975 | |||
| TOTAL ASSETS: | 351,153 | 233,188 | 281,435 | 333,467 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities, including: | 22,841 | 2,154 | 4,931 | 13,805 | |||
| Accounts payable | 9,870 | 759 | 1,659 | 2,078 | |||
| Accrued liabilities | 1,855 | 178 | 1,082 | 11,727 | |||
| Other undisclosed accounts payable and accrued liabilities | 11,116 | 1,217 | 2,190 | ||||
| Deferred revenue | 557 | 283 | |||||
| Other undisclosed current liabilities | 42 | 237 | 230 | 1,087 | |||
| Total current liabilities: | 23,440 | 2,391 | 5,444 | 14,892 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation: | 4,760 | ||||||
| Liabilities, other than long-term debt | 1,532 | 37 | 3,105 | ||||
| Accounts payable and accrued liabilities | |||||||
| Deferred revenue | 1,532 | 2,854 | |||||
| Operating lease, liability | 37 | 251 | 4,760 | ||||
| Other undisclosed noncurrent liabilities | 69,383 | (4,760) | |||||
| Total noncurrent liabilities: | 70,915 | 37 | 3,105 | 4,760 | |||
| Total liabilities: | 94,355 | 2,428 | 8,549 | 19,652 | |||
| Equity | |||||||
| Equity, attributable to parent | 256,798 | 230,760 | 272,886 | 313,815 | |||
| Common stock | 10 | 10 | 9 | 4 | |||
| Additional paid in capital | 379,873 | 362,004 | 349,408 | 500,349 | |||
| Accumulated other comprehensive income (loss) | 220 | 49 | 407 | (326) | |||
| Accumulated deficit | (123,305) | (131,303) | (76,938) | (186,212) | |||
| Total equity: | 256,798 | 230,760 | 272,886 | 313,815 | |||
| TOTAL LIABILITIES AND EQUITY: | 351,153 | 233,188 | 281,435 | 333,467 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|---|
| Revenues | 89,149 | 30 | 1,316 | |||
| Gross profit: | 89,149 | 30 | 1,316 | |||
| Operating expenses | (92,232) | (67,550) | (36,832) | (89,584) | ||
| Operating loss: | (3,083) | (67,520) | (35,516) | (89,584) | ||
| Nonoperating income | 11,369 | 13,155 | 834 | |||
| Investment income, nonoperating | (140) | |||||
| Other nonoperating income | 11,369 | 13,155 | 974 | |||
| Income (loss) from continuing operations before income taxes: | 8,286 | (54,365) | (34,682) | (89,584) | ||
| Income tax expense | (288) | |||||
| Other undisclosed loss from continuing operations | ||||||
| Income (loss) from continuing operations: | 7,998 | (54,365) | (34,682) | (89,584) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (89,584) | |
| Net income (loss): | 7,998 | (54,365) | (34,682) | (89,584) | ||
| Other undisclosed net income attributable to parent | 106 | |||||
| Net income (loss) available to common stockholders, diluted: | 7,998 | (54,365) | (34,682) | (89,478) | ||
Comprehensive Income ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | 7,998 | (54,365) | (34,682) | (89,584) | ||
| Other comprehensive income (loss) | 8,169 | (54,723) | (34,275) | (89,804) | ||
| Other undisclosed comprehensive income | ||||||
| Comprehensive income (loss): | 16,167 | (109,088) | (68,957) | (179,388) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (7,998) | 54,365 | 34,682 | 89,584 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 8,169 | (54,723) | (34,275) | (89,804) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.